三、结语
AD作为老年性痴呆的主要类型,严重影响老年人的身心健康及生活质量,成为日趋严峻的全球问题。目前,对于AD的治疗尚缺乏有效的手段,因此对风险较高的人群进行筛查、早期诊断、早期干预显得尤为重要。生物标志物和分子影像的引入为AD的早期和准确诊断提供了重要手段。AD 的诊断正从传统临床诊断思维向结合生物标志物和分子影像学方法进行诊断和鉴别诊断的方向发展。
参考文献
[1]Liu YH,Wang YR,Xiang Y,et al.Clearance of amyloid-beta in Alzheimer's disease:shifting the action site from center to periphery[J].Mol Neurobiol,2015,51(1):1-7.
[2]De Kimpe L,Scheper W.From alpha to omega with Abeta:targeting the multiple molecular appearances of the pathogenic peptide in Alzheimer's disease[J].Curr Med Chem,2010,17(3):198-212.
[3]余抒,府伟灵.阿尔茨海默病及诊断学研究进展[J].临床检验杂志,2016,34(1):49-51.
[4]Scheltens P,Blennow K,Breteler MM,et al.Alzheimer's disease[J].Lancet,2016,388(10043):505-517.
[5]乔莉霞,陈升东.阿尔茨海默病的早期诊断研究进展[J].中华脑科疾病与康复杂志:电子版,2016,6(1):50-52.
[6]Wurtman R.Biomarkers in the diagnosis and management of Alzheimer's disease[J].Metabolism,2015,64(3):S47-S50.
[7]De Meyer G,Shapiro F,Vanderstichele H,et al.Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people[J].Arch Neurol,2010,67(8):949-956.
[8]Bernard C,Helmer C,Dilharreguy B,et al.Time course of brain volume changes in the preclinical phase of Alzheimer's disease[J].Alzheimers Dement,2014,10(2):143-151.
[9]Blennow K,Hampel H,Weiner M,et al.Cerebrospinal fluid and plasma biomarkers in Alzheimer disease[J].Nat Rev Neurol,2010,6(3):131-144.
[10]Blennow K,de Leon MJ,Zetterberg H.Alzheimer's disease[J].Lancet,2006,368(9533):387-403.
[11]Moghekar A,Li S,Lu Y,et al.CSF biomarker changes precede symptom onset of mild cognitive impairment[J].Neurology,2013,81(20):1753-1758.
[12]Noguchi-Shinohara M,Komatsu J,Samuraki M,et al.Cerebral amyloid angiopathy-related microbleeds and cerebrospinal fluid biomarkers in Alzheimer's disease[J].J Alzheimers Dis,2017,55(3):905-913.
[13]Samgard K,Zetterberg H,Blennow K,et al.Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity[J].Int J Geriatr Psychiatry,2010,25(4):403-410.
[14]Lleo A,Cavedo E,Parnetti L,et al.Cerebrospinal fluid biomarkers in trials for Alzheimer and Parkinson diseases[J].Nat Rev Neurol,2015,11(1):41-55.
[15]Isaac M,Vamvakas S,Abadie E,et al.Qualification opinion of novel methodologies in the predementia stage of Alzheimer's disease:cerebro-spinal-fluid related biomarkers for drugs affecting amyloid burden-regulatory considerations by European Medicines Agency focusing in improving benefit/risk in regulatory trials[J].Eur Neuropsychopharmacol,2011,21(11):781-788.
[16]Savage MJ,Kalinina J,Wolfe A,et al.A sensitive abeta oligomer assay discriminates Alzheimer's and aged control cerebrospinal fluid[J].J Neurosci,2014,34(8):2884-2897.
[17]Diez-Guerra FJ.Neurogranin,a link between calcium/calmodulin and protein kinase C signaling in synaptic plasticity[J].IUBMB Life,2010,62(8):597-606.
[18]Kvartsberg H,Duits FH,Ingelsson M,et al.Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease[J].Alzheimers Dement,2015,11(10):1180-1190.
[19]Brinkmalm A,Brinkmalm G,Honer WG,et al.SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease[J].Mol Neurodegener,2014,9:53.
[20]Schupf N,Patel B,Silverman W,et al.Elevated plasma amyloid betapeptide 1-42 and onset of dementia in adults with Down syndrome[J].Neurosci Lett,2001,301(3):199-203.
[21]Whiley L, Sen A, Heaton J, et al.Evidence of altered phosphatidylcholine metabolism in Alzheimer's disease[J].Neurobiol Aging,2014,35(2):271-278.
[22]郝建华,李江,何亮,等.阿尔茨海默病患者尿中AD7c-NTP检测的意义[J].中国热带医学,2011,11(8):993-994.
[23]曾瀛,徐丽君,唐震宇,等.阿尔茨海默病患者尿液中相关的神经丝蛋白的诊断价值[J].中国老年学杂志,2013,53(13):3058-3060.(https://www.daowen.com)
[24]Teipel SJ,Schapiro MB,Alexander GE,et al.Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome[J].Am J Psychiatry,2003,160(10):1870-1878.
[25]Karas G,Scheltens P,Rombouts S,et al.Precuneus atrophy in earlyonset Alzheimer's disease:a morphometric structural MRI study[J].Neuroradiology,2007,49(12):967-976.
[26]Jack CJ,Lowe VJ,Weigand SD,et al.Serial PIB and MRI in normal,mild cognitive impairment and Alzheimer's disease:implications for sequence of pathological events in Alzheimer's disease[J].Brain,2009,132(Pt 5):1355-1365.
[27]Fleisher AS,Sun S,Taylor C,et al.Volumetric MRI vs clinical predictors of Alzheimer disease in mild cognitive impairment[J].Neurology,2008,70(3):191-199.
[28]Chetelat G,Landeau B,Eustache F,et al.Using voxel-based morphometry to map the structural changes associated with rapid conversion in MCI:a longitudinal MRI study[J].Neuroimage,2005,27(4):934-946.
[29]Likeman M,Anderson VM,Stevens JM,et al.Visual assessment of atrophy on magnetic resonance imaging in the diagnosis of pathologically confirmed young-onset dementias[J].Arch Neurol,2005,62(9):1410-1415.
[30]Kitamura S,Kiuchi K,Taoka T,et al.Longitudinal white matter changes in Alzheimer's disease:a tractography-based analysis study[J].Brain Res,2013,1515:12-18.
[31]Chen Y,Wolk DA,Reddin JS,et al.Voxel-level comparison of arterial spin-labeled perfusion MRI and FDG-PET in Alzheimer disease[J].Neurology,2011,77(22):1977-1985.
[32]Celone KA,Calhoun VD,Dickerson BC,et al.Alterations in memory networks in mild cognitive impairment and Alzheimer's disease:an independent component analysis[J].J Neurosci,2006,26(40):10222-10231.
[33]Teipel SJ,Schapiro MB,Alexander GE,et al.Relation of corpus callosum and hippocampal size to age in nondemented adults with Down's syndrome[J].Am J Psychiatry,2003,160(10):1870-1878.
[34]Sorg C,Riedl V,Muhlau M,et al.Selective changes of resting-state networks in individuals at risk for Alzheimer's disease[J].Proc Natl Acad Sci U S A,2007,104(47):18760-18765.
[35]Goveas JS,Xie C,Ward BD,et al.Recovery of hippocampal network connectivity correlates with cognitive improvement in mild Alzheimer ' s disease patients treated with donepezil assessed by resting-state fMRI[J].J Magn Reson Imaging,2011,34(4):764-773.
[36]Dolan MC,Fullam RS.Psychopathy and functional magnetic resonance imaging blood oxygenation level-dependent responses to emotional faces in violent patients with schizophrenia[J].Biol Psychiatry,2009,66(6):570-577.
[37]Steven AJ,Zhuo J,Melhem ER.Diffusion kurtosis imaging:an emerging technique for evaluating the microstructural environment of the brain[J].AJR Am J Roentgenol,2014,202(1):W 26-W 33.
[38]Kim EJ,Cho SS,Jeong Y,et al.Glucose metabolism in early onset versus late onset Alzheimer's disease:an SPM analysis of 120 patients[J].Brain,2005,128(Pt 8):1790-1801.
[39]Drzezga A,Grimmer T,Riemenschneider M,et al.Prediction of individual clinical outcome in MCI by means of genetic assessment and(18)F-FDG PET[J].J Nucl Med,2005,46(10):1625-1632.
[40]Camus V,Payoux P,Barre L,et al.Using PET with 18F-AV-45(florbetapir)to quantify brain amyloid load in a clinical environment[J].Eur J Nucl Med Mol Imaging,2012,39(4):621-631.
[41]Mistur R,Mosconi L,Santi SD,et al.Current challenges for the early detection of alzheimer's disease:Brain imaging and CSF studies[J].J Clin Neurol,2009,5(4):153-166.
[42]Okamura N,Harada R,Furukawa K,et al.Advances in the development of tau PET radiotracers and their clinical applications[J].Ageing Res Rev,2016,30:107-113.
[43]Watanabe H,Ono M,Saji H.Novel PET/SPECT probes for imaging of tau in Alzheimer's disease[J].Scientific World Journal,2015,2015:124192.
[44]Visser P J,Verhey F,Knol D L,et al.Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study:a prospective cohort study[J].Lancet Neurol,2009,8(7):619-627.
[45]乔莉霞,陈升东.阿尔茨海默病的早期诊断研究进展[J].中华脑科疾病与康复杂志:电子版,2016,6(1):50-52.
[46]Kromer R,Serbecic N,Hausner L,et al.Comparison of visual evoked potentials and retinal nerve fiber layer thickness in Alzheimer's disease[J].Front Neurol,2013,4:203.
(高 擎 张颖冬)